Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Madrigal Pharmaceuticals

30/07/2026 18:10

Madrigal Pharmaceuticals Inc MDGL.OQ reported a quarterly adjusted loss of $1.13​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.90.  The mean expectation of seventeen analysts for the quarter was for a loss of $2.57 per share. Wall Street expected results to range from $-4.18 to $-1.29 per share.
Revenue rose 71.2% to $364.25 million from a year ago; analysts expected $353.18 million. 
Madrigal Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.99​.
The company reported a quarterly loss of $57.94 million.
Madrigal Pharmaceuticals Inc shares had risen by 1.8% this quarter and lost 6.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 146.6% in the last three months.​ 
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Madrigal Pharmaceuticals Inc is $659.50, about 17.1% above its last closing price of $546.88
This summary was machine generated from LSEG data July 30 at 05:10 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-2.57
-1.13
Beat
Mar. 31 2026 
-4.03
-3.25
Beat
Dec. 31 2025 
-0.67
-2.57
Missed
Sep. 30 2025 
-2.08
-4.96
Missed